Back to Search
Start Over
Gilead announces PURPOSE 2 met efficacy endpoints, reduced HIV infections by 96%
- Source :
- The Fly. September 12, 2024
- Publication Year :
- 2024
-
Abstract
- Gilead announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.808437706